JOHNSON B KRISTINE 4
4 · ClearPoint Neuro, Inc. · Filed May 21, 2026
Research Summary
AI-generated summary of this filing
ClearPoint Neuro (CLPT) Director Kristine B. Johnson Receives RSU Shares
What Happened
Kristine B. Johnson, a director of ClearPoint Neuro, had 12,417 restricted stock units (RSUs) settle into 12,417 shares of ClearPoint Neuro common stock on May 19, 2026. The Form 4 shows an exercise/conversion of a derivative (Transaction Code M) and the corresponding issuance of shares; no per-share price or cash value is reported in the filing. This was the scheduled vesting/settlement of an award rather than an open‑market purchase or sale.
Key Details
- Transaction date: May 19, 2026 (reported on Form 4 filed May 21, 2026). Filing appears timely.
- Shares acquired: 12,417 shares (settlement of RSUs). The filing also records the cancellation/conversion of 12,417 derivative units.
- Price/Value: N/A in the filing (no cash consideration reported).
- Footnote: The RSUs were originally granted May 22, 2025 and vested on the earlier of the first anniversary of the grant or the day before the company’s 2026 annual meeting; this transaction represents the scheduled settlement of those RSUs.
- Shares owned after transaction: not specified in this filing.
Context
This transaction reflects routine equity compensation vesting for a director (an award settlement), not a purchase or sale that signals a change in conviction. For derivative entries, the M code here denotes conversion/exercise of a derivative (RSU → common shares). No immediate sale or cashless exercise is indicated.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1]2026-05-19+12,417→ 71,116 total - Exercise/Conversion
Restricted Stock Units
[F1]2026-05-19−12,417→ 0 total→ Common Stock (12,417 underlying)
Footnotes (1)
- [F1]Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.